|
Select publications
Albain KS et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs paclitaxel
(T) as frontline therapy for metastatic breast cancer (MBC): First report of overall
survival. Proc ASCO 2004;Abstract 510.
Carlson RW et al. Goserelin plus anastrozole for the treatment of premenopausal women
with hormone receptor positive, recurrent/metastatic breast cancer. San Antonio Breast
Cancer Symposium 2004. Abstract 6052.
Gnant M et al. Zoledronic acid effectively counteracts cancer treatment induced bone
loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine
treatment with goserelin plus anastrozole versus goserelin plus tamoxifen — Bone
density subprotocol results of a randomized multicenter trial (ABCSG-12). San Antonio
Breast Cancer Symposium 2004;Abstract 6.
Gradishar WJ et al. Capecitabine plus paclitaxel as front-line combination therapy for
metastatic breast cancer: A multicenter phase II study. J Clin Oncol 2004;22(12):2321-7.
Abstract
Hennessy BT et al. Lower dose capecitabine has a more favorable therapeutic index in
metastatic breast cancer: Retrospective analysis of patients treated at M. D. Anderson
Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005;16(8):1289-96. Abstract
Howell A et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma:
A prospectively planned combined survival analysis of two multicenter trials. Cancer 2005;104(2):236-9. Abstract
Howell A et al. Comparison of fulvestrant versus tamoxifen for the treatment of
advanced breast cancer in postmenopausal women previously untreated with endocrine
therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004; 22(9): 1605-
13. Abstract
Jones SE, Pippen J. Effectiveness and tolerability of fulvestrant in postmenopausal women
with hormone receptor-positive breast cancer. Clin Breast Cancer 2005;6(Suppl 1):9-14.
Abstract
Kudachadkar R, O’Regan RM. Aromatase inhibitors as adjuvant therapy for postmenopausal
patients with early stage breast cancer. CA Cancer J Clin 2005;55(3):145-63. Abstract
Leonard R et al. Optimizing the management of HER2-negative metastatic breast
cancer with capecitabine (Xeloda). Semin Oncol 2004;31(5 Suppl 10):21-8. Abstract
O’Shaughnessy J et al. Superior survival with capecitabine plus docetaxel combination
therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial
results. J Clin Oncol 2002; 20(12): 2812-23. Abstract
O’Shaughnessy J. A retrospective evaluation of the impact of dose reduction in patients
treated with Xeloda (capecitabine). Proc ASCO 2000;Abstract 400.
Pierga JY et al. Efficacy and safety of single agent capecitabine in pretreated metastatic
breast cancer patients from the French compassionate use program. Breast Cancer Res Treat 2004;88(2):117-29. Abstract
Pippen J et al. Fulvestrant (Faslodex) versus anastrozole (Arimidex) for the treatment of
advanced breast cancer: A prospective combined survival analysis of two multicenter
trials. Poster. San Antonio Breast Cancer Symposium 2003. Abstract
Robertson JF et al. Fulvestrant versus anastrozole for the treatment of advanced breast
carcinoma in postmenopausal women: A prospective combined analysis of two multicenter
trials. Cancer 2003;98(2):229-38. Abstract
Sledge GW et al. Phase III trial of doxorubicin, paclitaxel, and the combination of
doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An
intergroup trial (E1193). J Clin Oncol 2003;21(4):588-92. Abstract
Walko CM, Lindley C. Capecitabine: A review. Clin Ther 2005;27(1):23-44. Abstract
|
